The estimated Net Worth of Chad Patterson is at least $4.38 Million dollars as of 31 May 2024. Mr Patterson owns over 3,012 units of Dexcom Inc stock worth over $2,542,497 and over the last 3 years he sold DXCM stock worth over $1,837,822.
Mr has made over 10 trades of the Dexcom Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 3,012 units of DXCM stock worth $224,876 on 31 May 2024.
The largest trade he's ever made was selling 3,012 units of Dexcom Inc stock on 31 May 2024 worth over $224,876. On average, Mr trades about 597 units every 66 days since 2021. As of 31 May 2024 he still owns at least 37,133 units of Dexcom Inc stock.
You can see the complete history of Mr Patterson stock trades at the bottom of the page.
Chad M. Patterson is the Exec. VP of Global Marketing at Dexcom Inc.
Mr Patterson is 39, he's been the Exec. VP of Global Marketing of Dexcom Inc since . There are 29 older and no younger executives at Dexcom Inc. The oldest executive at Dexcom Inc is Andrew K. Balo, 73, who is the Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel..
Chad's mailing address filed with the SEC is C/O IRHYTHM TECHNOLOGIES, INC, 699 8TH ST #600, SAN FRANCISCO, CA, 94103.
Over the last 20 years, insiders at Dexcom Inc have traded over $724,717,982 worth of Dexcom Inc stock and bought 165,450 units worth $3,489,100 . The most active insiders traders include Sean Carney, Kim D Blickenstaff, and Steven R Altman. On average, Dexcom Inc executives and independent directors trade stock every 7 days with the average trade being worth of $892,438. The most recent stock trade was executed by Sadie Stern on 9 September 2024, trading 426 units of DXCM stock currently worth $29,458.
founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.
Dexcom Inc executives and other stock owners filed with the SEC include: